Shots:

• Allarity to receive an up front license fee & regulatory milestones for each program while Oncoheroes will receive commercialization rights based on Allarity’s 1st buy-back option. If Allarity does not exercise the buy-back option, it will eligible for clinical/regulatory milestones along with royalties on sales of stenoparib & dovitinib.
•  Oncoheroes obtains an exclusive right globally to fund & conduct clinical development of both products in pediatric cancers. Allarity will support Oncoheroes’ pediatric trials by providing access to its DRP companion diagnostic for patients selection
• Allarity has submitted an NDA to the US FDA for dovitinib in RCC along with Dovitinib-DRP companion diagnostic

Ref: Allarity | Image: Linkedin